Current management of hypertrophic cardiomyopathy

Article

Opinion statement

Hypertrophic cardiomyopathy is a heterogeneous clinical syndrome with a wide spectrum of pathophysiologic consequences. Most cases are inherited and caused by sarcomeric protein gene mutations, although phenocopies are often encountered. Genomic research and family studies have improved our recognition of the disease and understanding of its natural history; however, tenuous links exist between genotype and phenotype and thus far have done little to alter clinical management. Surgery and, more recently, implantable cardiac defibrillators have had an impact on sudden cardiac death rates, with improved short-and medium-term survival. Therefore, managing heart failure has become increasingly challenging. Although heart failure due to fibrosis and a progressive loss of contractile function is common, treatment remains largely empiric. Case series and animal studies suggest that biventricular pacing and renin-angiotensin-aldosterone system modifiers may be useful in some patients, but there is a need for large prospective randomized controlled trials to study these and other treatments. Risk stratification and eligibility for sports participation remain hot topics, but one of the greatest challenges is the management of a growing cohort of asymptomatic gene carriers identified during family screening. Ultimately, major advances in treatment and disease prevention will come from a better understanding of the genomic, proteomic, and metabolomic profiles of individual patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Elliott P, McKenna WJ: Hypertrophic cardiomyopathy. Lancet 2004, 363:1881–1891.PubMedCrossRefGoogle Scholar
  2. 2.
    Maron BJ: Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287:1308–1320.PubMedCrossRefGoogle Scholar
  3. 3.
    Arad M, Seidman JG, Seidman CE: Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet 2002, 11:2499–2506.PubMedCrossRefGoogle Scholar
  4. 4.
    Hilfiker-Kleiner D, Knoll R: Disease-modifying mutations in familial hypertrophic cardiomyopathy: complexity from simplicity. Circulation 2008, 117:1775–1777.PubMedCrossRefGoogle Scholar
  5. 5.
    Keren A, Syrris P, McKenna WJ: Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 2008, 5:158–168.PubMedCrossRefGoogle Scholar
  6. 6.
    Elliott P, Andersson B, Arbustini E, et al.: Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008, 29:270–276.PubMedCrossRefGoogle Scholar
  7. 7.
    Maron BJ, Towbin JA, Thiene G, et al.: Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006, 113:1807–1816.PubMedCrossRefGoogle Scholar
  8. 8.
    Maron BJ, McKenna WJ, Danielson GK, et al.: American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003, 42:1687–1713.PubMedCrossRefGoogle Scholar
  9. 9.
    Maron MS, Olivotto I, Zenovich AG, et al.: Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006, 114:2232–2239.PubMedCrossRefGoogle Scholar
  10. 10.
    Maron MS, Olivotto I, Betocchi S, et al.: Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003, 348:295–303.PubMedCrossRefGoogle Scholar
  11. 11.
    Sherrid MV, Pearle G, Gunsburg DZ: Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 1998, 97:41–47.PubMedGoogle Scholar
  12. 12.
    Harrison DC, Braunwald E, Glick G, et al.: Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 1964, 29:84–98.PubMedGoogle Scholar
  13. 13.
    Hubner PJ, Ziady GM, Lane GK, et al.: Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy. Br Heart J 1973, 35:1116–1123.PubMedCrossRefGoogle Scholar
  14. 14.
    Ostman-Smith I, Wettrell G, Riesenfeld T: A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 1999, 34:1813–1822.PubMedCrossRefGoogle Scholar
  15. 15.
    Epstein SE, Rosing DR: Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981, 64:437–441.PubMedGoogle Scholar
  16. 16.
    Rosing DR, Kent KM, Maron BJ, Epstein SE: Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 1979, 60:1208–1213.PubMedGoogle Scholar
  17. 17.
    Pollick C, Kimball B, Henderson M, Wigle ED: Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol 1988, 62:1248–1251.PubMedCrossRefGoogle Scholar
  18. 18.
    Sherrid MV, Barac I, McKenna WJ, et al.: Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005, 45:1251–1258.PubMedCrossRefGoogle Scholar
  19. 19.
    McKenna WJ, Oakley CM, Krikler DM, Goodwin JF: Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985, 53:412–416.PubMedCrossRefGoogle Scholar
  20. 20.
    Maron BJ, Olivotto I, Bellone P, et al.: Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 39:301–307.PubMedCrossRefGoogle Scholar
  21. 21.
    Biagini E, Coccolo F, Ferlito M, et al.: Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005, 46:1543–1550.PubMedCrossRefGoogle Scholar
  22. 22.
    Tsybouleva N, Zhang L, Chen S, et al.: Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004, 109:1284–1291.PubMedCrossRefGoogle Scholar
  23. 23.
    Lim DS, Lutucuta S, Bachireddy P, et al.: Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001, 103:789–791.PubMedGoogle Scholar
  24. 24.
    Araujo AQ, Arteaga E, Ianni BM, et al.: Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 2005, 96:1563–1567.PubMedCrossRefGoogle Scholar
  25. 25.
    Spirito P, Rapezzi C, Bellone P, et al.: Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. Circulation 1999, 99:2132–2137.PubMedGoogle Scholar
  26. 26.
    Wilson W, Taubert KA, Gewitz M, et al.: Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007, 116:1736–1754.PubMedCrossRefGoogle Scholar
  27. 27.
    Team NSCGT: Prophylaxis Against Infective Endocarditis in Adults and Children Undergoing Interventional Procedures. London: National Institute for Health and Clinical Excellence; 2008.Google Scholar
  28. 28.
    Olivotto I, Ommen SR, Maron MS, et al.: Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol 2007, 50:831–834.PubMedCrossRefGoogle Scholar
  29. 29.
    Woo A, Williams WG, Choi R, et al.: Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005, 111:2033–2041.PubMedCrossRefGoogle Scholar
  30. 30.
    Ommen SR, Maron BJ, Olivotto I, et al.: Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005, 46:470–476.PubMedCrossRefGoogle Scholar
  31. 31.
    Seggewiss H, Rigopoulos A, Welge D, et al.: Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 2007, 96:856–863.PubMedCrossRefGoogle Scholar
  32. 32.
    Maron BJ, Nishimura RA, McKenna WJ, et al.: Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999, 99:2927–2933.PubMedGoogle Scholar
  33. 33.
    Kappenberger L, Linde C, Daubert C, et al.: Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study PIC. Study Group. Eur Heart J 1997, 18:1249–1256.PubMedGoogle Scholar
  34. 34.
    Kilicaslan F, Verma A, Saad E, et al.: Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 2006, 3:275–280.PubMedCrossRefGoogle Scholar
  35. 35.
    Gaita F, Di Donna P, Olivotto I, et al.: Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2007, 99:1575–1581.PubMedCrossRefGoogle Scholar
  36. 36.
    Jeanrenaud X, Schlapfer J, Fromer M, et al.: Dual chamber pacing in hypertrophic obstructive cardiomyopathy: beneficial effect of atrioventricular junction ablation for optimal left ventricular capture and filling. Pacing Clin Electrophysiol 1997, 20:293–300.PubMedCrossRefGoogle Scholar
  37. 37.
    Ashrafian H, Mason MJ, Mitchell AG: Regression of dilated-hypokinetic hypertrophic cardiomyopathy by biventricular cardiac pacing. Europace 2007, 9:50–54.PubMedCrossRefGoogle Scholar
  38. 38.
    Rogers DP, Marazia S, Chow AW, et al.: Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. Eur J Heart Fail 2008, 10:507–513.PubMedCrossRefGoogle Scholar
  39. 39.
    Lenarczyk R, Kowalski O, Kukulski T, et al.: Resynchronization or dyssynchronization-successful treatment with biventricular stimulation of a child with obstructive hypertrophic cardiomyopathy without dyssynchrony. J Cardiovasc Electrophysiol 2007, 18:542–544.PubMedCrossRefGoogle Scholar
  40. 40.
    Biagini E, Spirito P, Leone O, et al.: Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol 2008, 101:387–392.PubMedCrossRefGoogle Scholar
  41. 41.
    Elliott PM, Gimeno JR, Thaman R, et al.: Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006, 92:785–791.PubMedCrossRefGoogle Scholar
  42. 42.
    Elliott PM, Poloniecki J, Dickie S, et al.: Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000, 36:2212–2218.PubMedCrossRefGoogle Scholar
  43. 43.
    Zipes DP, Camm AJ, Borggrefe M, et al.: ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006, 27:2099–2140.PubMedCrossRefGoogle Scholar
  44. 44.
    Watkins H: Sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:422–424.PubMedCrossRefGoogle Scholar
  45. 45.
    Maron BJ, Maron MS, Lesser JR, et al.: Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol 2008, 101:544–547.PubMedGoogle Scholar
  46. 46.
    Moon JC, McKenna WJ, McCrohon JA, et al.: Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41:1561–1567.PubMedCrossRefGoogle Scholar
  47. 47.
    Maron BJ, Spirito P: Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 1998, 81:1339–1344.PubMedCrossRefGoogle Scholar
  48. 48.
    Maron BJ, Seidman JG, Seidman CE: Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 44:2125–2132.PubMedCrossRefGoogle Scholar
  49. 49.
    Autore C, Conte MR, Piccininno M, et al.: Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40:1864–1869.PubMedCrossRefGoogle Scholar
  50. 50.
    Thompson RC, Liberthson RR, Lowenstein E: Perioperative anesthetic risk of noncardiac surgery in hypertrophic obstructive cardiomyopathy. JAMA 1985, 254:2419–2421.PubMedCrossRefGoogle Scholar
  51. 51.
    Pelliccia A, Fagard R, Bjornstad HH, et al.: Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005, 26:1422–1445.PubMedCrossRefGoogle Scholar
  52. 52.
    Maron BJ, Chaitman BR, Ackerman MJ, et al.: Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004, 109:2807–2816.PubMedCrossRefGoogle Scholar
  53. 53.
    Maron BJ, Moller JH, Seidman CE, et al.: Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. A statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association. Circulation 1998, 98:1460–1471.Google Scholar
  54. 54.
    Corrado D, Pelliccia A, Bjornstad HH, et al.: Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005, 26:516–524.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.The Heart HospitalLondonUK

Personalised recommendations